Effect of Subconjunctival Anti-VEGF Conbercept as an Adjuvant to the surgical treatment of pterygium

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012546

Enrollment

Unknown

Registered

2017-09-01

Start date

2017-09-07

Completion date

Unknown

Last updated

2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium

Interventions

conbercept group:subconjunctival injection of conbercept

5-Fu group:subconjunctival injection of 5-Fu

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. all subjects with pterygium encroaching into cornea more than 2mm from the limbus have been recruited; 2. Aged 50-70 years old.

Exclusion criteria

Exclusion criteria: 1. with other ocular disease, such as keratonosus, crystal dislocation, glaucoma, shallow anterior chamber, uveitis, retinal diseases, congenital anomalies, regurgitation from the lacrimal puncta (indicating nasolacrimal duct obstruction), ocular trauma, or autoimmune diseases and so on; 2. being allergic to Conbercept; 3. uncontrolled diabetes or hypertension, other medical conditions increasing the risk of complications for surgery; 4. pregnancy or lactation women; 5. unable to accept subsequent review on schedule.

Design outcomes

Primary

Measure	Time frame
pterygium morphology;color intensity;recurrence;	—

Countries

China

Contacts

Public ContactKe Min

Zhongnan Hospital of Wuhan University

keminyk@163.com+86 18672395959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026